The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic.
SHANGHAI and HONG KONG, March 6, 2024 /PRNewswire/ — Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that four preclinical abstracts have been selected as poster presentations at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.
"The promising data we are about to present at this year’s AACR Annual Meeting underscore Antengene’s ongoing focus on the innovation of oncology drugs, our strong in-house expertise in developing antibody and small molecule therapies and impressive platform innovations," said Dr. Bing Hou, Antengene’s Head of Discovery Science & Translational Medicine. "Tumor selective epigenetic inhibitors is one of the areas of focus for Antengene. At the meeting, we will present the first data from our MTAPnull-selective PRMT5 inhibitor program and the first candidate from our companion diagnostic program, a CDx to support our novel Claudin 18.2 ADC, ATG-022. In addition, we are keenly interested in T cell engagers and look forward to presenting results on Antengene’s unique AnTenGager™ platform and one of our first lead programs targeting LILRB4 for Acute Myelogenous Leukemia (AML). Building on those promising results, we will forge ahead with our innovative work for the benefit of more cancer patients around the world."
Details of the posters:
ATG-042 (MTAPnull-selective PRMT5 Inhibitor)Title: Preclinical characterization of ATG-042, a novel MTAPnull-selective PRMT5 inhibitorAbstract: 4592Session Category: Experimental and Molecular TherapeuticsSession Title: HDAC and Methyltransferase InhibitorsDate: April 9, 2024Time: 9:00 AM – 12:30 PM (Pacific Time) 12:00 AM – 3:30 AM, April 10, 2024 (Beijing Time)Location: Poster Section 24
Companion Diagnostic Antibody for ATG-022 (Claudin 18.2 ADC)Title: Development of a novel companion diagnostic immunohistochemistry antibody for Claudin 18.2-targeted therapiesAbstract: 1032Session Category: Clinical ResearchSession Title: Diagnostic Biomarkers 1Date: April 7, 2024Time: 1:30 PM – 5:00 PM (Pacific Time) 4:30 AM – 8:00 AM, April 8, 2024 (Beijing Time)Location: Poster Section 42
AnTenGagerTM PlatformTitle: AnTenGagerTM, a novel "2+1" T cell engager platform, enables conditional T cell activation with reduced risk of CRSAbstract: 6343Session Category: Clinical ResearchSession Title: Antibodies 2Date: April 9, 2024Time: 1:30 PM – 5:00 PM (Pacific Time) 4:30 AM – 8:00 AM, April 10, 2024 (Beijing Time)Location: Poster Section 41
ATG-102 (LILRB4 x CD3 T Cell Engager)Title: ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two non-overlapping epitopes of LILRB4, for the treatment of monocytic AMLAbstract: 2372Session Category: Clinical ResearchSession Title: Antibodies 1Date: April 8, 2024Time: 9:00 AM – 12:30 PM (Pacific Time) 12:00 AM – 3:30 AM, April 9, 2024 (Beijing Time)Location: Poster Section 38
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to the Hong Kong Stock Exchange.
Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158
PR Contacts:Peter QianE-mail: Peter.Qian@antengene.com Mobile: +86 13062747000
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
